Canon
Hardware manufacturer with a razor-and-blade consumables engine (printers + toner/ink recurring) plus capital equipment (semiconductor lithography, medical imaging systems), premium optics/camera ecosystem (RF-mount lens lock-in), and a growing network-video/security software+hardware arm (Axis, Milestone). Majority of sales are outside Japan — high FX translation exposure.
Earnings, margins, COGS & capex
FY2025 delivered record net sales of JPY 4,624.7B (+2.5%) with operating profit JPY 455.4B (~9.8% margin) and net income attributable to Canon of JPY 332.1B (~7.2% margin). Growth was led by Imaging (mirrorless upcycle), with Medical and Industrial modestly up and Printing (the largest segment, ~half of sales) roughly flat under secular office-print pressure. FY2026 opened weak: Q1 sales rose 3.3% but operating profit fell 26.1% and net income fell 33.1% on higher component/memory costs, U.S. tariffs and printing softness; management guides FY2026 to record sales (JPY 4,765B, +3.0%) but only roughly flat profit (OP JPY 456B, +0.1%; NI JPY 333B, +0.3%).
Income statement — where each revenue dollar goes
% of revenueOf every $1 of revenue, ~53¢ is cost of goods and ~37¢ operating expense, leaving ~10¢ of operating profit (~7¢ net).
Revenue trend
Margins
up vs FY2024; guided roughly flat FY2026
up YoY; Q1 FY2026 compressed (-33% NI)
positive, self-funding dividend + buybacks
pressured in 2026 by memory/component cost + tariffs
COGS structure
Cost base is component-heavy: image sensors, semiconductors/memory (DRAM), optical glass and precision mechanical parts; rising memory prices and new U.S. tariffs were cited as the primary FY2026 gross-margin headwinds. Printing consumables (toner/ink) carry high gross margins and anchor blended profitability.
Capex
Not precisely disclosed in this pass; structurally elevated by the capital-equipment (semiconductor/display lithography) and medical-imaging manufacturing footprint. FY2025 free cash flow ~JPY 269B (est.) implies capex materially below operating cash flow (FY2024 OCF ~JPY 606.8B).
Latest earnings
Profit sharply down YoY — margin miss vs prior year on memory-cost inflation, U.S. tariffs and printing weakness; top line still grew to a record Q1
FY2026: net sales JPY 4,765B (+3.0%, record), operating profit JPY 456B (+0.1%), net income JPY 333B (+0.3%); Canon Inc (7751) dividend JPY 160/yr (JPY 80 interim + 80 year-end), ~40% target payout, ~3.8% ADR yield
- Q1 FY2026 net sales
- JPY 1,093.7B (+3.3%)
- Q1 FY2026 operating profit
- JPY 71.4B (-26.1%)
- Q1 FY2026 net income
- JPY 48.3B (-33.1%)
- FY2026 dividend (Canon Inc 7751)
- JPY 160/share (~40% payout)
Growth drivers
- Imaging: mirrorless (EOS R system) refresh and premium interchangeable-lens share (Canon-claimed #1 for 20+ consecutive years) — RF-mount lens ecosystem lock-in
- Industrial: AI-driven semiconductor capex lifting demand for lithography (i-line/KrF steppers, nanoimprint NIL) and sputtering/OLED display equipment
- Medical: Canon Medical (ex-Toshiba Medical) CT/MRI/ultrasound on U.S. orders and emerging-market demand; aging-population secular tailwind
- Network video / security: Axis Communications + Milestone software — structural growth offsetting print
- Commercial/production printing (inkjet, digital presses) partly offsetting office-print volume decline
Bull & bear
A cheap, cash-generative diversified franchise where growth in imaging, semiconductor/display equipment, medical and network-video is quietly re-weighting the mix away from declining office print — with a ~3.8% dividend and low double-digit P/E offering downside support while the story plays out.
- Valuation is undemanding: ~11x FY2025 earnings and ~3.8% yield with a ~40% payout and buybacks — a value/income anchor
- Imaging is in a genuine mirrorless upcycle with durable #1 interchangeable-lens share and lens-ecosystem lock-in
- Industrial rides the AI/semiconductor capex wave (lithography, sputtering, OLED equipment); nanoimprint is optionality, not priced in
- Medical + network-video (Axis/Milestone) provide secular, less-cyclical growth that improves the long-run mix
- Strong balance sheet and cash flow self-fund shareholder returns even through a soft-profit 2026
- Yen weakness (if sustained) flatters reported overseas earnings
The engine is still printing — a structurally declining, ~half-of-sales business — and 2026 shows the growth segments can't yet offset cost inflation, tariffs and print erosion, with Q1 operating profit down 26% and full-year profit guided flat; a Japan-conglomerate discount, FX risk and no leading-edge litho position cap the upside.
- Q1 FY2026 operating profit -26% and net income -33% YoY — the margin story is deteriorating, not improving
- FY2026 guidance is record sales but flat profit: revenue growth isn't converting to earnings
- Office-print secular decline is the gravity on ~half the business; commercial print only partly offsets
- Memory/component cost inflation and U.S. tariffs are real, recurring margin headwinds
- Not a leading-edge lithography player — the semiconductor upside is niche vs ASML dominance and adoption of nanoimprint is unproven
- Yen appreciation would reverse the translation tailwind; conglomerate structure invites a persistent valuation discount
- No U.S. exchange listing (OTC ADR only) reduces liquidity and index eligibility for U.S. investors
What it is worth
Peer-multiple + dividend-yield cross-check (P/E ~11x FY2025 EPS, ~3.8% ADR yield); trades at a discount to focused Western imaging/medical/equipment peers reflecting a Japan-conglomerate discount + office-print secular overhang.
De-rating or flat if office-print erosion accelerates, tariffs/memory costs persist, or the yen appreciates and reverses the translation tailwind — earnings stagnate and the discount widens.
Range-bound value/income name: ~11x earnings, ~3.8% yield, low-single-digit revenue growth with flat-to-modest profit; total return led by the dividend.
Re-rating toward mid-teens P/E if growth-mix shift + buybacks lift EPS and 2026 is a cost trough — plus a sustained ~4% yield; implies meaningful upside from ~$26 ADR.
~JPY 3.7T (~$23B) market cap on ~JPY 332B net income implies ~11x earnings; low EV/EBITDA and a well-covered ~40%-payout dividend give downside support. Re-rating hinges on the growth segments (imaging, semiconductor/display equipment, medical, network-video) out-weighing print decline and on FY2026 proving to be a cost-driven trough rather than a trend.
SWOT
Strengths
- Diversified across printing, imaging, medical and industrial — no single end-market dominates, smoothing cyclicality
- Large printing installed base with high-margin recurring toner/ink consumables
- World-leading optics/imaging IP — Canon-claimed #1 interchangeable-lens share for 20+ years with RF-mount lens lock-in
- Strong balance sheet and cash generation funding a ~3.8% dividend + buybacks
- Niche capital-equipment franchises (semiconductor lithography incl. nanoimprint, medical imaging, OLED/sputtering) with high barriers to entry
Weaknesses
- Core printing segment (~half of sales) faces secular office-print-volume decline from hybrid work and digitization
- Heavy FX translation exposure — most sales overseas; earnings swing with the yen
- Not a leading-edge lithography player — ceded advanced nodes to ASML; confined to mature nodes + unproven nanoimprint
- 2026 margin compression from memory/component cost inflation and U.S. tariffs
- Japan-conglomerate complexity and slower capital-allocation cadence than focused Western peers
Opportunities
- AI/semiconductor capex supercycle lifting Industrial (lithography, back-end, OLED equipment)
- Nanoimprint lithography (NIL) as a lower-cost patterning path if adoption broadens beyond niche
- Network video/security (Axis, Milestone) as a software-led growth and margin-mix improver
- Medical imaging growth on aging demographics and emerging-market build-out
- Continued mirrorless premiumization and lens attach — possible re-rating from a low ~11x P/E if growth mix shifts
Threats
- Structural decline of office print accelerating faster than growth segments can offset
- U.S. tariffs and trade friction on Japan-manufactured hardware
- DRAM/memory and component cost inflation squeezing hardware margins
- Intense competition — Sony/Nikon (imaging), HP/Xerox/Ricoh (print), GE HealthCare/Siemens Healthineers/Philips (medical), ASML/Nikon (litho)
- Yen appreciation reversing the recent translation tailwind and capping reported earnings
- Smartphone cannibalization of the low-end camera market
Moats, dependencies & bottlenecks
Moats
High-margin recurring toner/ink on a huge installed base, but the base and print volumes are in secular decline.
Canon-claimed #1 interchangeable-lens share for 20+ years; owning a lens system locks users to the body brand.
High barriers and IP, but confined to mature nodes/niche; not competing at the leading edge where ASML dominates.
CT/MRI/ultrasound installed base and service revenue; scale below GE HealthCare/Siemens Healthineers/Philips.
Vertically integrated precision engineering and a globally trusted consumer/enterprise brand.
Dependencies
Hybrid work and digitization structurally shrink the largest segment's core consumable demand.
Macro / translation Majority of sales overseas; reported earnings swing materially with USD/EUR-JPY.
Industrial segment (lithography, sputtering, OLED equipment) tied to fab and display investment cycles.
Supply / input cost DRAM/memory price inflation and semiconductor availability directly hit hardware gross margin (cited FY2026 headwind).
Regulatory / trade New U.S. tariffs on imported hardware named as a 2026 margin drag.
Premium camera demand is discretionary and smartphone-substitutable at the low end.
Advantages
- Diversification across four large end-markets dampens single-market shocks
- Recurring high-margin printing consumables cash engine
- Dominant, sticky camera/lens ecosystem
- Optionality in nanoimprint lithography and AI-driven semiconductor/display equipment demand
- Under-appreciated network-video/security software-hardware franchise (Axis, Milestone)
- Strong balance sheet funding dividend + buybacks through a down-profit year
Weaknesses
- Growth segments not yet large enough to offset printing decline in reported profit
- 2026 profit going backwards despite record sales
- Heavy FX and cyclical (semiconductor) earnings sensitivity
- Discount valuation reflecting conglomerate + secular-decline overhang
- OTC-only U.S. access (no NYSE listing since 2023) limits U.S. investor liquidity/indexing
Bottlenecks
- Office-print secular decline capping the largest profit pool
- 2026 input-cost inflation (memory/components) and U.S. tariffs compressing margins
- No leading-edge lithography position — semiconductor upside limited to mature/niche nodes
- FX volatility making reported earnings hard to underwrite
- Conglomerate complexity slowing capital reallocation toward the fastest-growing segments
Top signals & trends
Top signals
Near-term margin deterioration from cost inflation, tariffs and print softness.
Revenue growth not converting to earnings this year.
Camera segment growth with leading interchangeable-lens share; Q1 camera sales up double digits.
Structural tailwind, though adoption of nanoimprint is unproven.
Value/income support even in a soft-profit year.
Trends
Hybrid work and digitization shrink the core consumable base.
Higher ASP mirrorless bodies + lens attach; Canon leads.
Lifts lithography, sputtering and OLED equipment demand.
Secular support for Canon Medical CT/MRI/ultrasound.
Axis + Milestone add software-led, higher-mix growth.
Direct 2026 gross-margin headwind on imported hardware.
Weak yen flatters reported earnings; appreciation reverses it.
Ecosystem & competitor graph
Suppliers feed the company; customers pull from it. Line thickness shows the strength of each tie (supply-chain dependency, customer earnings contribution). Hover to isolate a tie.
CMOS image sensors — supplier to parts of the camera market (Canon also makes its own sensors).
Foundry logic chips for Canon's electronics.
DRAM/memory — cost inflation here directly pressured FY2026 margins.
Optical glass & precision-materials suppliers Specialty glass, coatings and mechanical components for lenses and equipment.
Camera/lens buyers — discretionary, brand-loyal to the RF ecosystem.
offices & commercial print shops Office MFPs, production inkjet/digital presses and toner/ink consumables.
Canon Medical CT/MRI/ultrasound systems and service.
Buyers of Canon lithography, sputtering and display equipment (Industrial).
Mirrorless cameras (Alpha) and the dominant image-sensor supplier — both a rival and a supplier to the imaging value chain.
Direct rival in interchangeable-lens cameras AND in semiconductor/FPD lithography steppers.
Leading rival in office and consumer printing / imaging supplies.
Office/production print and managed print services competitor (now owns Lexmark).
Japanese office-print and multifunction-printer rival.
Inkjet and business printing competitor; strong in consumer/inkjet.
Office/production print and diagnostic-imaging competitor.
SMB/consumer printing competitor.
Top-tier medical-imaging competitor (CT/MRI) to Canon Medical.
Global medical-imaging leader; strong CT/MRI franchise.
Medical-imaging and diagnostics competitor.
Dominates advanced-node lithography where Canon does not compete; bounds Canon's semiconductor-equipment upside to mature/niche + nanoimprint.
Overlaps in imaging, medical (diagnostics/imaging) and materials — diversified Japanese peer.